This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

SIGA Shares Leap On Likely Gov't Contract

NEW YORK (AP) â¿¿ Shares of biodefense company SIGA Technologies Inc. rose more than 19 percent Tuesday after government actions signaled that the company is a top contender to supply millions of doses of smallpox treatment for a national stockpile.

THE SPARK: In October, SIGA won a version of the deal that required that some of the money go to small businesses. However, a smaller competitor protested to the Small Business Administration. The SBA agreed with the smaller company, Chimerix Inc., based in Durham, N.C., calling SIGA "other than small." Last week, however, the government scrapped its request for proposals. A replacement RFP was nearly identical, but omitted the rules about small business participation.

Analysts said the new RFP, issued on behalf of the Biomedical Advanced Research and Development Authority, is designed to make SIGA the only viable bidder.

THE BIG PICTURE: The government's purchasing rules encourage contracts with small businesses and other types of protected companies. The requirements are written into RFPs. Removing them often is a sign that the government prefers a particular company that fails to satisfy some qualification.

THE ANALYSIS: The government gave bidders exactly a week to submit their responses. It often takes longer to prepare a complete, competitive submission. "The new RFP. . . is, in our opinion, a procedural maneuver that now allows BARDA to issue a contract to SIGA," Wedbush Securities analysts wrote in a research note Tuesday.

The analysts "strongly" reiterated an "Outperform" rating on the stock, saying the contract, if awarded, calls for 1.7 million courses, valued at $500 million, with a potential follow-on contract valued at $2.8 billion. "We anticipate an ongoing annual demand of approximately 1.5 million doses to be worth $225 million in annual sales to SIGA," they wrote.

SIGA, based in New York, makes and supplies drugs used to treat and prevent infectious diseases including those in biological weapons.

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
SYM TRADE IT LAST %CHG

Markets

DOW 17,826.30 -279.47 -1.54%
S&P 500 2,081.18 -23.81 -1.13%
NASDAQ 4,931.8150 -75.9760 -1.52%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs